首页 | 本学科首页   官方微博 | 高级检索  
     


Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor
Authors:William G. Wierda  John C. Byrd  Matthew S. Davids  Richard R. Furman  Bruce D. Cheson  Paul M. Barr  Herbert Eradat  Leonard Heffner  Lang Zhou  Maria Verdugo  Jalaja Potluri  Michael Choi
Affiliation:1. University of Texas MD Anderson Cancer Center, Houston, TX;2. Department of Medicine, College of Medicine, and Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH;3. Dana-Farber Cancer Institute, Boston, MA;4. Weill Cornell Medicine, New York, NY;5. Georgetown University Hospital, Washington, DC;6. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY;7. University of California Los Angeles, Los Angeles, CA;8. Emory University School of Medicine, Atlanta, GA;9. AbbVie Inc., North Chicago, IL;10. University of California San Diego, San Diego, CA
Abstract:
Keywords:venetoclax  chronic lymphocytic leukaemia  B-cell receptor signalling pathway inhibitor  relapsed  refractory
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号